Global Cryoablation Devices Market 2017-2021
About Cryoablation Devices
Cryoablation is a process that uses extreme cold to destroy diseased tissue. It employs a cryogenic material, such as liquid nitrogen, to freeze cancer cells. It is considered as an effective treatment modality for prostate cancer (transrectal ultrasound is used to guide hollow probes/needles that are inserted through the anus to the prostate) and is also used for the treatment of other cancers of the bone, cervix, lungs, and liver.
Technavio’s analysts forecast the global cryoablation devices market to grow at a CAGR of 6.10% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global cryoablation devices market for 2017-2021. To calculate the market size, the report considers revenue generated from the sales, volume, and value of cryoablation devices.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Cryoablation Devices Market 2017-2021
Technavio recognizes the following companies as the key players in the global cryoablation devices market: Medtronic, Galil Medical, and CooperSurgical.
Other Prominent Vendors in the market are: ACS Myanmar Medical, AtriCure, BVM Medical, CPSI Biotech, ForTec Medical, HealthTronics, IRANBEHDASHT, ICECURE MEDICAL, METRUM CRYOFLEX, RA Distribution, and Solution Medical.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is paradigm shift toward minimally invasive procedures. Cryoablation is considered as one of the effective and minimally invasive procedures, which uses frigid temperatures to kill cancer cells while preserving the surrounding tissues. According to reports published by Galil Medical, doctors all over the world have been using cryoablation to treat different types of cancer.”
According to the report, one driver in the market is safe and effective treatment for AVNRT patients. AVNRT is the second most common form of paroxysmal recurrent tachycardia in children. RA ablation has become the first-line therapy for AVNRT, with high success and low recurrence rates. However, a definite risk of damage to the atrioventricular (AV) node still exists. Cryoablation procedure provides a distinct advantage adjacent to the AV node for para-Hisian pathways and difficult cases of AVNRT, which cannot be performed by conventional RA ablation.
Further, the report states that one challenge in the market is high cost of cryoablation devices and procedures. The cost of cryosurgeries involving cryoablation devices is more than that of the RF procedures. AF ablation requires the use of expensive technology and equipment. Physicians have considerable latitude in equipment choice. The average Medicare reimbursement is $10,338 for uncomplicated AF ablations. The treatment of cardiac arrhythmia can be resolved either by the RF ablation or by the cryoablation procedure.
Medtronic, Galil Medical, CooperSurgical, ACS Myanmar Medical, AtriCure, BVM Medical, CPSI Biotech, ForTec Medical, HealthTronics, IRANBEHDASHT, ICECURE MEDICAL, METRUM CRYOFLEX, RA Distribution, and Solution Medical